Network Biology Lab

Network Biology Lab

NETWORK BIOLOGY

Many of the current generation of cancer therapeutics target components of signalling pathways, being either small molecule kinase inhibitors or monoclonal antibodies to cell surface receptors. Whilst these individual proteins and pathways represent attractive therapeutic targets, it is fast becoming apparent that the inherent flexibility of signalling pathways mean that targeting a single pathway component can lead to rapid network adaptation and the emergence of a resistant sub-population of tumour cells.

The Network Biology research group focuses on the investigation of network level aberrations induced by oncogenes and oncogenic mutations, ultimately aiming to elucidate how these altered network states lead to therapeutic resistance.